Previous 10 | Next 10 |
Esperion Therapeutics Anticipates Positive News For Two Of Its Drug Candidates Esperion Therapeutics ( ESPR ) is on the verge of a major catalyst as the company awaits the FDA decision for bempedoic acid as a treatment for increased LDL cholesterol. The agency is scheduled to deliver its...
Noteworthy events during the week of February 16 - 22 for healthcare investors. More news on: Agile Therapeutics, Inc., Merck & Co., Inc., Cellectar Biosciences, Inc., Healthcare stocks news, , Read more ...
Curaleaf (CURA CN) initiated with Neutral rating and C$11.40 (41% upside) price target at Cantor Fitzgerald. U.S. ticker: ( OTCPK:CURLF ). More news on: Curaleaf Holdings, Inc., Pfenex Inc., Trulieve Cannabis Corp., Healthcare stocks news, Stocks on the move, , Read more ...
CounterPath (NASDAQ: CPAH ) +49% on securing five-year deal with Vodafone Fiji to extend superior quality voice services to consumers. More news on: CounterPath Corporation, Alpha Pro Tech, Ltd., NanoViricides, Inc., Stocks on the move, , Read more ...
Upcoming Catalysts FDA approval of BA and BA+EZ (Feb. '20) EMA approval of BA and BA+EZ (1Q '20) BA marketization & revenue earnings (2H '20) CVOT data (2023) Introduction Shares of Esperion Therapeutics (ESPR) are up 64% and nearly 50% relative to the general market ( ...
Going into the second month of this new year, biotech investors have a lot to look forward to. In particular, there are many promising drug candidates awaiting approval from the Food and Drug Administration (FDA), as well as a number of well-established drugs that are on the cusp of receiving ex...
Esperion Therapeutics ( ESPR ) has two upcoming PDUFA dates scheduled at the end of February for their bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are expected to treat elevated low-density lipoprotein cholesterol "LDL-C". Both of these prod...
The European Medicines Agency's (EMA) advisory group has voted in favor of approving two new cholesterol-lowering medicines developed by biopharmaceutical company Esperion Therepeutics (NASDAQ: ESPR) . Following the positive opinion from the Committee for Medicinal Products for Human Use (CHM...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing approval of Esperion Therapeutics' (NASDAQ: ESPR ) fixed-dose combination of bempedoic acid and ezetimibe, branded as Nustendi, for the treatment of hypercholesterolemia and mixed dyslipidemia. FGK w...
– Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism – – Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 Fixed Do...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...